vs
合众银行（FSBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是REGENXBIO Inc.的1.5倍（$45.1M vs $30.3M），合众银行净利率更高（41.3% vs -221.3%，领先262.6%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 21.3%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FSBC vs RGNX — 直观对比
营收规模更大
FSBC
是对方的1.5倍
$30.3M
净利率更高
FSBC
高出262.6%
-221.3%
两年增速更快
RGNX
近两年复合增速
21.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $30.3M |
| 净利润 | $18.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 41.3% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 42.0% | -31.2% |
| 每股收益（稀释后） | $0.87 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCRGNX
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $30.3M | ||
| Q3 25 | $41.3M | $29.7M | ||
| Q2 25 | $38.3M | $21.4M | ||
| Q1 25 | $35.3M | $89.0M | ||
| Q4 24 | $35.2M | $21.2M | ||
| Q3 24 | $31.8M | $24.2M | ||
| Q2 24 | $30.7M | $22.3M |
净利润FSBCRGNX
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $-67.1M | ||
| Q3 25 | $16.3M | $-61.9M | ||
| Q2 25 | $14.5M | $-70.9M | ||
| Q1 25 | $13.1M | $6.1M | ||
| Q4 24 | $13.3M | $-51.2M | ||
| Q3 24 | $10.9M | $-59.6M | ||
| Q2 24 | $10.8M | $-53.0M |
毛利率FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -190.0% | ||
| Q3 25 | 53.8% | -176.3% | ||
| Q2 25 | 52.4% | -296.3% | ||
| Q1 25 | 52.0% | 13.6% | ||
| Q4 24 | 55.1% | -242.1% | ||
| Q3 24 | 48.0% | -256.6% | ||
| Q2 24 | 49.4% | -251.3% |
净利率FSBCRGNX
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | -221.3% | ||
| Q3 25 | 39.6% | -208.3% | ||
| Q2 25 | 37.9% | -331.8% | ||
| Q1 25 | 37.1% | 6.8% | ||
| Q4 24 | 37.9% | -241.3% | ||
| Q3 24 | 34.4% | -246.3% | ||
| Q2 24 | 35.2% | -237.7% |
每股收益（稀释后）FSBCRGNX
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $-1.30 | ||
| Q3 25 | $0.77 | $-1.20 | ||
| Q2 25 | $0.68 | $-1.38 | ||
| Q1 25 | $0.62 | $0.12 | ||
| Q4 24 | $0.61 | $-0.99 | ||
| Q3 24 | $0.52 | $-1.17 | ||
| Q2 24 | $0.51 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $458.5M | $102.7M |
| 总资产 | $5.0B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSBCRGNX
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
股东权益FSBCRGNX
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $102.7M | ||
| Q3 25 | $431.3M | $161.5M | ||
| Q2 25 | $416.7M | $213.7M | ||
| Q1 25 | $406.5M | $274.2M | ||
| Q4 24 | $396.6M | $259.7M | ||
| Q3 24 | $389.9M | $301.4M | ||
| Q2 24 | $380.5M | $348.3M |
总资产FSBCRGNX
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $453.0M | ||
| Q3 25 | $4.6B | $525.2M | ||
| Q2 25 | $4.4B | $581.0M | ||
| Q1 25 | $4.2B | $490.9M | ||
| Q4 24 | $4.1B | $466.0M | ||
| Q3 24 | $3.9B | $519.1M | ||
| Q2 24 | $3.6B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $-52.3M | ||
| Q3 25 | $18.8M | $-56.0M | ||
| Q2 25 | $17.8M | $-49.3M | ||
| Q1 25 | $15.5M | $33.6M | ||
| Q4 24 | $51.8M | $-31.6M | ||
| Q3 24 | $17.5M | $-40.5M | ||
| Q2 24 | $16.0M | $-45.5M |
自由现金流FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | $-52.8M | ||
| Q3 25 | $18.6M | $-56.5M | ||
| Q2 25 | $17.5M | $-49.7M | ||
| Q1 25 | $15.4M | $32.6M | ||
| Q4 24 | $51.2M | $-32.7M | ||
| Q3 24 | $17.3M | $-40.9M | ||
| Q2 24 | $15.8M | $-46.0M |
自由现金流率FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | -174.0% | ||
| Q3 25 | 45.0% | -189.9% | ||
| Q2 25 | 45.8% | -232.8% | ||
| Q1 25 | 43.5% | 36.6% | ||
| Q4 24 | 145.5% | -154.2% | ||
| Q3 24 | 54.5% | -168.9% | ||
| Q2 24 | 51.6% | -206.2% |
资本支出强度FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 1.8% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% |
现金转化率FSBCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | 5.53× | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
